Click on image to view larger version.
FIGURE 1. Dosimetric data published for principal PRRT trials: (A) 111In-DTPA-octreotide (Stabin (13), Forster (22), Helish (23), Kwekkeboom (14)). (B) 90Y-DOTATOC (Cremonesi (15), Forster (22), Helish (23), Forrer (16)). (C) 177Lu-DOTATATE (Kwekkeboom (30)). Large ranges of variability emerge, even in large cohort of patients. This suggests that mean values of absorbed doses among patients should not be the only criterion to plan PRRT. Besides the methods used for dosimetry, interindividual differences are attributable, especially to organ functionality, metabolism, or receptor density in organs.
